Privatna Urologicka Ambulancia s.r.o.
- Address
- lock Available on a paid plan
Metastatic Hormone-sensitive Prostate Cancer
The urology department at Privatna Urologicka Ambulancia s.r.o. is evaluating new targeted regimens for patients with PTEN deficiency, aiming to extend radiographic progression‑free survival.
- Capivasertib plus Abiraterone combination therapy
- Investigator‑assessed radiographic progression‑free survival
- Biomarker‑driven patient stratification
These studies seek to improve first‑line treatment options for men with advanced disease.
Metastatic Castration-resistant Prostate Cancer
Ongoing trials focus on combining androgen‑receptor blockade with PARP inhibitors such as Olaparib and Talazoparib to enhance disease control.
- PARP inhibitor plus enzalutamide regimens
- Evaluation of radiographic progression‑free survival
- Safety monitoring in treatment‑experienced patients
The goal is to offer effective options for men whose cancer has progressed despite standard hormone therapy.
High‑risk Recurrent Prostate Cancer after Prostatectomy
Researchers are testing an intensified adjuvant approach that adds Apalutamide to radiotherapy and LHRH agonist, with disease monitoring by PSMA‑PET.
- Adjuvant therapy with apalutamide
- Advanced imaging for early metastasis detection
- Assessment of time to metastatic progression
This work aims to reduce the risk of distant spread in patients with previously treated high‑risk disease.
Genetic and Cellular Mechanisms in Prostate Cancer
The clinic investigates underlying HRR deficiencies and other genetic alterations to personalize therapy across the prostate cancer spectrum.
- Genomic profiling for targeted treatment selection
- Study of cell physiological pathways influencing tumor growth
- Exploration of microbiological phenomena impacting the tumor microenvironment
Findings are expected to guide future precision‑medicine strategies at the site.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Pfizer Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Privatna Urologicka Ambulancia s.r.o.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3) | Pfizer Inc. | Phase III | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enzalutamide | 5 | Unknown | 2016-11-29 | 2026-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.